Pyridoxamine lowers oxalate excretion and kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.

Scheinman JI, Voziyan PA, Belmont JM, Chetyrkin SV, Kim D, Hudson BG
Urol Res. 2005 33 (5): 368-71

PMID: 16292584 · DOI:10.1007/s00240-005-0493-3

In order to prevent kidney stones and nephrolithiasis in hyperoxaluria, a new treatment that specifically reduces oxalate production and therefore urinary oxalate excretion would be extremely valuable. Pyridoxamine(PM) could react with the carbonyl intermediates of oxalate biosynthesis, glycolaldehyde and glyoxylate, and prevent their metabolism to oxalate. In PM treated rats, endogenous urinary oxalate levels were consistently lower and became statistically different from controls after 12 days of experiment. In ethylene glycol-induced hyperoxaluria, PM treatment resulted in significantly lower (by ~50%) levels of urinary glycolate and oxalate excretion compared to untreated hyperoxaluric animals, as well as in a significant reduction in calcium oxalate crystal formation in papillary and medullary areas of the kidney. These results, coupled with favorable toxicity profiles of PM in humans, show promise for the therapeutic use of PM in primary hyperoxaluria and other kidney stone diseases.

MeSH Terms (11)

Animals Calcium Oxalate Crystallization Hyperoxaluria, Primary Kidney Liver Male Oxalates Pyridoxamine Rats Rats, Sprague-Dawley

Connections (4)

This publication is referenced by other Labnodes entities: